Autoantiybodies against Islet Cell Antigens

Indirect Immunofluorescence Test: Primate Pancreas

Detection of antibodies against islet cells.
Indications: Differentiation between a late manifestation of diabetes type 1 (latent autoimmune diabetes in adulthood, LADA) and diabetes type 2.
For a reliable determination of antibodies against islet cells an extended incubation time of 18 hours for the patient serum must be observed. The incubation time may be reduced to 2 hours but this will lead to a decrease in the sensitivity of the antibody detection test.
Standardised control with JDF units available (order no. CA 1021-0101-1).
With indirect immunofluorescence autoantibodies against pancreas islets (ICA) can be detected in 80% of patients with new-onset diabetes type 1. Two target antigens of ICA have been identified so far: the enzymes glutamic acid decarboxylase (GAD) and tyrosine phosphatase (IA2).
This BIOCHIP may be supplemented with further substrates, e. g. primate cerebellum for the detection of antibodies against GAD.
The microscopic evaluation can be significantly simplified by using small BIOCHIPs (1 x 1 mm). The BIOCHIPs appear almost completely in the field of view and facilitate finding the islet cells, thus rendering a time-consuming search unnecessary, especially in negative samples.

Monospecific detection of antibodies against glutamic acid decarboxylase (GAD), tyrosine phosphatase (IA2) or bispecific detection of both antibodies in a single reagent well.
Indications: early diagnosis of diabetes mellitus type 1, risk prediction in first grade relatives, prognosis of the clinical progression of diabetes type 1 for prediction of insulin dependence, differential diagnosis in gestational diabetes, differentiation between a late manifestation of diabetes type 1 (latent autoimmune diabetes in adulthood, LADA) and diabetes type 2.
Use of undiluted samples. Similar incubation conditions and times. Manual or automated test performance.
Multipoint calibration. The quantitation is based on an international reference preparation (NIBSC 97/550).
GAD and IA2: human, recombinant antigens.

	Antigen		Order No.
	Glutamic acid decarboxylase (GAD)		EA 1022-9601 G
	Tyrosine phosphatase (IA2)		EA 1023-9601 G
	GAD/IA2 Pool		EA 1022-9601-1 G

Monospecific detection of antibodies against glutamic acid decarboxylase (GAD), tyrosine phosphatase (IA2) and insulin.
Indications: Early diagnosis of diabetes mellitus type 1, risk prediction in first grade relatives, prognosis of the clinical progression of diabetes type 1 for prediction of insulin dependence, differential diagnosis in gestational diabetes, differentiation between a late manifestation of diabetes type 1 (latent autoimmune diabetes in adulthood, LADA) and diabetes type 2.
Use of undiluted samples. Similar incubation conditions and times. Manual or automated test performance.
Test kit formats for 50 or 100 determinations.
GAD and IA2: human, recombinant, 125I-labelled antigens, insulin: human, synthetic, 125I-labelled antigen.

	Antigen		Order No.
	Glutamic acid decarboxylase (GAD)		RA 1022-####
	Tyrosine phosphatase (IA2)		RA 1023-####
	Insulin		RA 1024-####